
    
      The purpose of this registry is to compile characteristics of world-wide outcomes for the use
      of Boston Scientific's commercially available Vercise DBS system in the treatment of
      Parkinson's disease.

      Subjects' improvement in disease symptoms and overall Quality of life will be assessed during
      the study following DBS and compared with baseline. Additionally, the utilization of Guide XT
      (GXT) System when used as a planning tool for programming of patients is also evaluated.
    
  